Dlin-MC3-DMA: Ionizable Lipid Standard for Lipid Nanoparticle siRNA & mRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is a potent ionizable cationic liposome lipid central to advanced lipid nanoparticle (LNP) formulations for siRNA and mRNA therapeutics. It demonstrates approximately 1000-fold greater hepatic gene silencing efficacy than its precursor DLin-DMA, with an ED50 of 0.005 mg/kg in mice for transthyretin (TTR) silencing. Dlin-MC3-DMA is neutral at physiological pH, reducing systemic toxicity, and becomes cationic at acidic endosomal pH to facilitate endosomal escape. Its performance has been validated in both empirical and machine learning-optimized studies (Wang et al., 2022, DOI), and is cited as a gold standard in LNP-mediated gene delivery workflows, including vaccine development. APExBIO supplies Dlin-MC3-DMA (SKU: A8791) for research use (product page).

Biological Rationale

Lipid nanoparticles (LNPs) are the most effective delivery systems for therapeutic nucleic acids such as siRNA and mRNA. Dlin-MC3-DMA is an ionizable cationic liposome lipid that facilitates the encapsulation and intracellular delivery of nucleic acids. Its structure allows for tight complexation with negatively charged nucleic acids at acidic pH, while minimizing interactions with serum proteins at physiological pH, thus reducing off-target effects and immunogenicity (Wang et al., 2022). The presence of Dlin-MC3-DMA in LNPs enhances hepatic gene silencing, making it suitable for applications in liver-targeted therapies and systemic mRNA vaccine delivery. The formulation typically includes DSPC, cholesterol, and PEGylated lipids to optimize particle stability and delivery efficiency.

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA operates via a pH-responsive mechanism. At physiological pH (~7.4), it is largely uncharged, which reduces toxicity and enhances circulation time. Upon endocytosis, the acidic endosomal environment (pH ~5.5–6.5) protonates the dimethylamino head group, converting Dlin-MC3-DMA into a cationic lipid. This charge switch destabilizes the endosomal membrane, facilitating endosomal escape and efficient cytosolic release of the nucleic acid payload (Wang et al., 2022). This mechanism is essential for the biological activity of siRNA and mRNA therapeutics, as cytosolic localization is required for gene silencing or translation, respectively.

Evidence & Benchmarks

• Dlin-MC3-DMA enables >1000-fold greater hepatic gene silencing efficacy compared to DLin-DMA in mouse models (ED50 for TTR silencing: 0.005 mg/kg) (Wang et al., Table 2).
• LNPs formulated with Dlin-MC3-DMA, DSPC, cholesterol, and PEG-DMG achieve superior in vivo delivery efficiency for both siRNA and mRNA versus other ionizable lipids (Wang et al., Figure 3).
• Machine learning models (LightGBM) predict and validate Dlin-MC3-DMA as a top-performing ionizable lipid for mRNA vaccine LNPs, outperforming SM-102 in mouse immunogenicity assays (Wang et al., Table 3).
• Dlin-MC3-DMA shows high solubility in ethanol (≥152.6 mg/mL) but is insoluble in water and DMSO, supporting its compatibility with standard LNP preparation protocols (APExBIO product page).
• Storage at -20°C or lower is required to maintain Dlin-MC3-DMA stability; solutions should be used promptly to prevent degradation (APExBIO).
• Recent reviews recognize Dlin-MC3-DMA as a gold standard for LNP-based siRNA and mRNA delivery, setting efficacy benchmarks for hepatic gene silencing and immunomodulatory therapies (Pepbridge.net).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is used extensively in:

• Lipid nanoparticle siRNA delivery for hepatic gene silencing, exemplified by knockdown of Factor VII and transthyretin (TTR).
• mRNA drug delivery lipid formulations for vaccines and therapeutic protein expression.
• Cancer immunochemotherapy and immunomodulatory mRNA therapies (lopermide.com—this article extends mechanistic insights by providing atomic-level benchmarks and recent machine learning validation, which were only summarized previously).
• Machine learning-guided LNP optimization for high-throughput screening and formulation prediction.

See also: mk2206.com (this article clarifies the quantitative potency data and storage/handling best practices omitted in previous summaries), and pepbridge.net (this piece updates with the latest machine learning benchmark data and endosomal escape mechanism details).

Common Pitfalls or Misconceptions

• Dlin-MC3-DMA is ineffective as a nucleic acid delivery vehicle when used alone, without helper lipids (DSPC, cholesterol, PEG-lipid).
• It is not suitable for direct aqueous formulation due to insolubility in water and DMSO.
• Neutral pH formulations do not support efficient endosomal escape; pH-dependent charge activation is critical.
• It is not a biodegradable lipid and can accumulate with repeated high-dose administration; this may limit chronic dosing regimens.
• Its ultra-high potency for hepatic gene silencing does not guarantee equivalent efficacy in non-liver tissues, as LNP biodistribution is organ-dependent.

Workflow Integration & Parameters

• Formulation: Typical LNP composition: Dlin-MC3-DMA:DSPC:Cholesterol:PEG-lipid at molar ratios ~50:10:38.5:1.5.
• Solubility: Soluble in ethanol (≥152.6 mg/mL); insoluble in water and DMSO (APExBIO).
• Storage: -20°C or below; solutions must be freshly prepared and used promptly.
• pH Sensitivity: Neutral at pH 7.4; protonates and becomes cationic at pH ≤6.5.
• ED50 (mouse, TTR silencing): 0.005 mg/kg; ED50 (NHP, TTR): 0.03 mg/kg (Wang et al., Table 2).
• Recommended workflow: Prepare LNPs by microfluidic mixing of ethanol-dissolved lipids with aqueous nucleic acid under controlled conditions (typically 4°C, rapid mixing, pH 4.0 citrate buffer).

Conclusion & Outlook

Dlin-MC3-DMA remains the reference ionizable lipid for LNP-mediated siRNA and mRNA delivery, validated across animal models and machine learning-guided studies. Its pH-triggered endosomal escape mechanism and high hepatic gene silencing potency anchor it at the forefront of nucleic acid delivery research. APExBIO (SKU: A8791) provides high-purity Dlin-MC3-DMA for research applications (product details). Future directions include optimization for extrahepatic delivery and biodegradable analogs to address chronic dosing limitations. For further molecular engineering insights, see this recent review (this article updates with new quantitative and ML-driven data for translational workflows).